Roxadustat

We are planning to advance roxadustat—our first-in-class, oral, small molecule product candidate for the treatment of anemia associated with LR-MDS—into Phase 3 clinical development.

​

Roxadustat, a hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor, promotes coordinated erythropoiesis by increasing endogenous erythropoietin, improving iron availability, and reducing hepcidin levels. Administration of roxadustat has been shown to increase red blood cell production while maintaining plasma erythropoietin levels within or near normal physiologic range in multiple subpopulations of CKD patients, including those with inflammation. Importantly, this effect occurs without the need for supplemental intravenous iron.

​

Roxadustat is approved in China, Europe, Japan, and numerous other countries for the treatment of anemia in CKD patients, both on and not on dialysis. Roxadustat is an investigational drug and is not approved for marketing anywhere in the world for anemia of LR-MDS.

​

Additional information about roxadustat trials currently recruiting patients can be found at